Brokerages Set UroGen Pharma Ltd. (NASDAQ:URGN) PT at $43.70

UroGen Pharma Ltd. (NASDAQ:URGN) has earned an average recommendation of “Buy” from the six analysts that are covering the company, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $39.20.

A number of brokerages have issued reports on URGN. D. Boral Capital reaffirmed a “buy” rating and set a $25.00 target price on shares of UroGen Pharma in a research report on Tuesday, February 18th. LADENBURG THALM/SH SH started coverage on UroGen Pharma in a research report on Wednesday, February 19th. They set a “buy” rating and a $31.00 target price on the stock.

Insider Transactions at UroGen Pharma

In other UroGen Pharma news, General Counsel Jason Drew Smith sold 7,379 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $82,202.06. Following the sale, the general counsel now owns 26,468 shares in the company, valued at $294,853.52. This represents a 21.80 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Mark Schoenberg sold 4,551 shares of UroGen Pharma stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $50,698.14. Following the sale, the insider now directly owns 145,666 shares of the company’s stock, valued at $1,622,719.24. The trade was a 3.03 % decrease in their position. The disclosure for this sale can be found here. 5.10% of the stock is currently owned by insiders.

Institutional Trading of UroGen Pharma

Several hedge funds have recently added to or reduced their stakes in the company. Barclays PLC lifted its stake in UroGen Pharma by 409.3% during the third quarter. Barclays PLC now owns 59,778 shares of the company’s stock worth $759,000 after purchasing an additional 48,040 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of UroGen Pharma by 263.1% in the third quarter. JPMorgan Chase & Co. now owns 68,062 shares of the company’s stock worth $864,000 after acquiring an additional 49,318 shares during the period. Geode Capital Management LLC increased its position in shares of UroGen Pharma by 8.1% during the third quarter. Geode Capital Management LLC now owns 455,637 shares of the company’s stock worth $5,787,000 after buying an additional 34,248 shares during the period. Vestal Point Capital LP acquired a new stake in UroGen Pharma during the third quarter worth approximately $5,080,000. Finally, Rice Hall James & Associates LLC grew its position in shares of UroGen Pharma by 273.6% during the 3rd quarter. Rice Hall James & Associates LLC now owns 271,897 shares of the company’s stock worth $3,453,000 after buying an additional 199,110 shares during the period. 91.29% of the stock is owned by institutional investors and hedge funds.

UroGen Pharma Trading Down 5.9 %

NASDAQ URGN opened at $10.08 on Wednesday. UroGen Pharma has a 1-year low of $9.78 and a 1-year high of $20.70. The firm’s fifty day simple moving average is $10.70 and its 200-day simple moving average is $12.13. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77. The company has a market capitalization of $236.38 million, a PE ratio of -3.20 and a beta of 1.08.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.